Haloperidol-induced potentiation of latent inhibition: Interaction with parameters of conditioning

Behavioural Pharmacology

Volumn 9, Issue 3, 1998, Pages 245-253

  Ruob, C ^a   Weiner, I ^b   Feldon, J ^a  

^a ETH ZURICH   (Switzerland)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dopamine; Haloperidol; Latent inhibition; Rat; Schizophrenia; Switching

Indexed keywords

HALOPERIDOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; MALE; NONHUMAN; RAT; REINFORCEMENT; SCHIZOPHRENIA;

ANIMALS; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; ELECTROSHOCK; HALOPERIDOL; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; STARTLE REACTION;

EID: 0031779624     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Baruch I, Hemsley DR, Gray JA (1988). Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Mental Dis 176:598-606.
2. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988). Haloperidol enhancement of latent inhibition: relation to therapeutic action. Biol Psychiatry 23:746-749.
3. Dunn LA, Atwater GE, Kilts CD (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal model of clinical drug action. Psychopharmacology 112:315-323.
4. Feldon J, Weiner I (1991). The latent inhibition model of schizophrenic attention disorder: haloperidol and sulpiride enhance rat's ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646.
5. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991). The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84.
6. Gray JA, Joseph MH, Hemsley DR, Young AMJ, Wartburton EC, Boulenguez P et al. (1995). The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71:19-31.
7. Gray NS, Hemsley DR, Gray JA (1992a). Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol, Psychiatry Brain Res 1:83-89.
8. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992b). Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107:425-430.
9. Gray NS, Pilowsky LS, Gray JA, Kerwin RW (1995). Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17:95-107.
10. Hall G (1991). Perceptual and associative learning, vol. 18. Oxford: Clarendon Press.
11. Killcross AS, Dickinson A, Robbins TW (1994a). Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology 115:185-195.
12. Killcross AS, Dickinson A, Robbins TW (1994b). Effects of the neuroleptic a-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 115:196-205.
13. Lubow RE (1973). Latent inhibition. Psychol Bull 79:398-407.
14. Lubow RE (1989). Latent inhibition and conditioned attention theory. Cambridge: Cambridge University Press.
15. Lubow RE, Gewirtz JC (1995). Latent inhibition in humans: data, theory, and implications for schizophrenia. Psychol Bull 117:87-103.
16. Lubow RE, Weiner I, Schnur P (1981). Conditioned attention theory. In Bower GH, editor. The psychology of learning and motivation. New York: Academic Press. pp. 1-49.
17. Mackintosh NJ (1975). A theory of attention: variations in the associability of stimuli with reinforcement. Psychol Rev 82:276-298.
18. Mackintosh NJ (1983). Conditioning and associative learning. New York: Oxford University Press.
19. Moore JW, Stickney KJ (1980). Formation of attentional-associative networks in real time: role of hippocampus and implications for conditioning. Physiol Psychol 8:207-217.
20. Peters SL, Joseph MH (1993). Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Phamacol 4:183-186.
21. Robbins TW (1990). The case of frontostriatal dysfunction in schizophrenia. Schizophr Bull 16:391-402.
22. Schmajuk NA, Moore JW (1985). Real-time attentional models for classical conditioning and the hippocampus. Physiol Psychol 13:278-290.
23. Schmajuk NA, Moore JW (1988). The hippocampus and the classically conditioned nictitating membrane response: a real-time attentional-associative model. Psychobiology 16:20-35.
24. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981). Disrupted latent inhibition in the rat with chronic amphetmine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537.
25. Thornton JC, Dawe S, Lee C, Capstick C, Corr PJ, Cotter P et al. (1996). Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology 127:164-173.
26. Weiner I (1990). Neural substrates of latent inhibition: the switching model. Psychol Bull 108:442-461.
27. Weiner I, Feldon J (1987). Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91:248-253.
28. Weiner I, Feldon J (1997). The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88:11-25.
29. Weiner I, Lubow RE, Feldon J (1981). Chronic amphetamine and latent inhibition. Behav Brain Res 2:285-286.
30. Weiner I, Lubow RE, Feldon J (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194-199.
31. Weiner I, Feldon J, Katz Y (1987). Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol, Biochem Behav 26:241-246.
32. Weiner I, Lubow RE, Feldon J (1988). Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol, Biochem Behav 30:871-878.
33. Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J (1994). The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav Pharmacol 5:119-124.
34. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic clozapine. Biol Psychiatry 40:834-843.
35. Weiner I, Bernasconi E, Broersen LM, Feldon J (1997a). Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus. Behav Pharmacol 8:442-457.
36. Weiner I, Shadach E, Barkai R, Feldon J (1997b). Halo-peridol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16:42-50.
37. Weiner I, Tarrasch R, Bernasconi E, Broersen LM, Rüttimann TC, Feldon J (1997c). Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated. Pharmacol, Biochem Behav 56:817-826.
38. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JNP (1996). Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized control trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry 40:1135-1143.
39. Williams JH, Wellman NA, Geaney DP, Feldon J, Cowen PJ, Rawlins JNP (1997). Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology 133:262-268.